Alan K. Davis, PhD, Fluence Lead Trainer
Thursdays, 5:30-7pm Eastern Time (EDT through November 6th/EST starting November 7th) from September 2nd to November 18th
$1,200 for 12-sessions
Optional CE certificate for $65
To obtain your certificate, the CE form must be filled out within 14 days of class completion.
A limited number of Diversity Fund scholarships are available, please complete this application.
This course can be taken in partial fulfillment of the requirements for the Fluence Postgraduate Certificate in Psychedelic Integration Therapy or Ketamine-assisted Psychotherapy.
This reading and study group will maintain the same membership for the 12-week period. The group will have a syllabus with readings that participants will be expected to read prior to each discussion group meeting. The format for each session will include a short review of each paper by the group leader, followed by a discussion of the content and group members’ perspectives of the topic. This is an active group and weekly participation is required. The group is ideal for clinicians, graduate students, researchers, or the public, so long as they have training or interest in the scientific understanding of evidenced-based clinical interventions and their integration in psychedelic therapy. Readings will primarily include papers in the academic literature. Topics will include coverage of several different evidenced-based therapies (e.g., ACT, MI, CBT, PE, DBT), several types of psychedelics (e.g., psilocybin, ayahuasca, MDMA, ibogaine), and a variety of clinical populations (e.g., depression, social anxiety, addiction).
Week 1: Review of Psychedelic Therapy
Week 2: Psilocybin for Depression
Week 3: Ibogaine Detoxification for Opioid Use Disorder
Week 4: Psilocybin for Long-term AIDS Survivors
Week 5: Therapeutic Mechanisms of Ayahuasca
Week 6: Psilocybin for Tobacco Addiction
Week 7: MDMA Therapy for PTSD with Couples
Week 8: Psilocybin for Alcohol Use Disorder
Week 9: Psychological Flexibility and Psychedelics
Week 10: MDMA for Autistic Adults
Week 11: Psychedelics and New Behaviorism
Week 12: Safety and Ethical Concerns of Psychedelic Therapy
At the end of the group, the participant will be able to:
1. Describe a variety of evidenced-based interventions that have been integrated into psychedelic-assisted psychotherapy studies
2. Explain the role of psychotherapy in psychedelic treatment across a variety of clinical populations
3. Critique the use of specific evidenced-based treatments as opposed to a supportive psychotherapeutic approach.
4. Describe the ethical concerns related to the provision of evidenced-based interventions within psychedelic therapy.
5. List the basic components of psychedelic therapy
6. Describe the ways in which the acute effects of psychedelics are related to psychotherapeutic processes.
7. Explain the safety concerns related to psychedelic therapy.
8. Compare the different approaches to psychedelic therapy and evidenced-based interventions
9. Explain the history of psychedelic therapy leading up to current trials.
10. Describe the basic pharmacology of psychedelic drugs.
11. List the features of the psychotherapeutic relationship that are critical to psychedelic interventions.
12. Explain the role of psychological flexibility and how this may be a transdiagnostic feature of evidenced-based interventions within the context of psychedelic therapy.
Information on Continuing Education Credit for Health Professionals (CE)